Zymeworks (NASDAQ:ZYME) Releases Earnings Results, Misses Expectations By $0.49 EPS

Zymeworks (NASDAQ:ZYME) issued its earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.49), FiscalAI reports. The firm had revenue of $2.41 million during the quarter, compared to the consensus estimate of $24.38 million. Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The firm’s revenue for the quarter was down 91.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.30) EPS.

Here are the key takeaways from Zymeworks’ conference call:

• Zanidatamab regulatory catalysts: U.S. PDUFA is set for August 25, 2026 for first?line HER2+ GEA and an sBLA was completed in China, creating near?term commercialization visibility and expected partner milestone payments (approximately $250M U.S., $50M China).
• Pan?RAS ADC platform progress: AACR disclosed three new pan?RAS ADC candidates with a proprietary payload showing tumor?selective accumulation, durable pathway inhibition, and encouraging non?human primate tolerability, supporting further development across RAS?driven cancers.
• ZW191 clinical signal: Phase I data showed strong activity in heavily pretreated ovarian (ORR 56% overall; 61% at 6.4–9.6 mg/kg) and endometrial cancer (ORR 40% overall; 57% at 6.4–9.6 mg/kg) with manageable cytopenias/GI events and ongoing dose optimization.
• Financial results show volatility: revenue fell to $2.4M (Q1 2026) from $27.1M a year earlier and net loss widened to $44.2M, driven by the absence of non?recurring 2025 milestones and declines in development support.
• Balance sheet and capital deployment: Cash and marketable securities were $403.8M at March 31, 2026, ~$95.8M of a $125M buyback executed (?3.93M shares), and management expects runway beyond 2028 assuming anticipated milestone payments (~$440M), supporting buybacks, partnerships, or M&A optionality.

Zymeworks Stock Down 3.7%

NASDAQ ZYME opened at $26.60 on Friday. The stock’s 50 day moving average is $25.62 and its 200 day moving average is $24.06. The firm has a market capitalization of $1.96 billion, a PE ratio of -24.63 and a beta of 1.20. Zymeworks has a twelve month low of $10.86 and a twelve month high of $29.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZYME. Stifel Nicolaus boosted their price target on Zymeworks from $40.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Leerink Partners lifted their price objective on Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a report on Monday, April 20th. HC Wainwright raised their price target on Zymeworks from $32.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Finally, Truist Financial raised shares of Zymeworks to a “strong-buy” rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $37.89.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP bought a new stake in shares of Zymeworks in the 3rd quarter worth approximately $50,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Zymeworks during the fourth quarter valued at $55,000. Tower Research Capital LLC TRC raised its position in shares of Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after purchasing an additional 1,131 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Zymeworks by 157.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company’s stock worth $129,000 after purchasing an additional 6,307 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new position in Zymeworks in the 2nd quarter worth about $133,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.